



A35422 (073513.0102)
PATENT

JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hu et al.

Application No.: 10/670,971

Examiner: Nguyen, Quang

Filed: September 24, 2003

Group Art Unit: 1636


For: EPIDERMAL MELANOCYTE CULTURE FORMULATIONS

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.

January 21, 2005
Date of Deposit

Peter J. Shen
Attorney's Name



52,217
Registration No.

January 21, 2005
Date of Signature

Mail Stop Amendment
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants bring to the attention of the Examiner the documents disclosed on the attached PTO 1449 and respectfully request that the listed documents be considered by the Examiner under 37 C.F.R. § 1.97(b)(3). In accordance with 37 C.F.R. § 1.56, Applicants respectfully request that the references relating to the above-mentioned application and listed in the accompanying PTO-1449 form be made of record

in the United States Patent and Trademark Office. Enclosed herewith are copies the listed references.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

This Information Disclosure Statement is being after the mailing date of a first office action on the merits. Thus, the Commissioner is authorized to charge the fee pursuant to 37 C.F.R. § 1.97(b)(3) to our Deposit Account No. 02-4377.

January 21, 2005

Respectfully submitted,


Peter J. Shen
PTO Registration No. 52,217

Attorney for Applicants
Baker Botts, LLP
(212) 408-2500

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANTS**

TRADEMARK OFFICE
Attorney Docket No.
A35422 (073513.0102)

Application No.
10/670,971

Applicants
Hu et al.

Filing Date
September 24, 2003

Group Art Unit
1636

U.S. PATENT DOCUMENTS

*Exam. Init.		Document No.	Date	Name	Class	Subclass	Filing Date ifAppropriate

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	SubClass	Translator Yes	No

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

1	Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest. Ophthalmol. Vis. Sci. 2002; 43, 2579-2583.
2	Boissy RE. Extracutaneous Melanocytes. In <u>The Pigmentary System</u> , Edited by Nordland JE et al. Oxford Univ. Press, Oxford, 1998. p. 68.
3	Boissy RE. The Melanocyte: Its structure, function, and subpopulations in skin, eye and hair. Dermatologic Clinics 1988; 6: 161-173.
4	Cohen Y, Goldberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe'er J, Sidransky D. Lack of BRAF mutation in primary melanoma. Invest. Ophthalmol. Vis. Sci. 2003, 44: 2876-2878.

NY02:505769.1

Examiner _____ Date Considered _____

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Attorney Docket No. A35422 (073513.0102)	Application No. 10/670,971
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		Applicants Hu et al.	
		Filing Date September 24, 2003	Group Art Unit 1636

5	Chen YF, Yang PY, Liang SF, Hu DN. Repigmentation of vitiligo following transplantation of autologous cultured melanocytes. Show-Chwan Med J. 1999; 1(2):85-90.
6	Chen YF, Chang JS, Yang PY, Hung CM, Huang MH, Hu DN. Transplant of cultured autologous pure melanocytes after laser-abrasion for the treatment of segmental vitiligo. J Dermatol. 2000 Jul;27(7):434-9.
7	Edmunds SC, Kelsell DP, Hungerford JL, Cree IA. Mutational analysis of selected genes in the TGF β , Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2002; 43: 2845-2851.
8	Hu DN, Woodward DF, McCormick SA. Influence of autonomic neurotransmitters on human uveal melanocytes in vitro. Exp Eye Res 2000; 71:217-24.
9	Hu DN. Regulation of growth and melanogenesis of uveal melanocytes. Pigment Cell Res 2000; 13 (Suppl. 8): 81-86.
10	Hu DN, Woodward DF, McCormick SA. Influence of autonomic neurotransmitters on human uveal melanocytes in vitro. Exp Eye Res. 2000 Sep;71(3):217-24.
11	Hu DN, Stjernschantz J, McCormick SA. Effect of prostaglandins A(2), E(1), F(2 alpha)and latanoprost on cultured human iridal melanocytes. Exp Eye Res. 2000 Jan;70(1):113-20.
12	Hu DN, McCormick SA, Lin AY, Lin JY. TGF-beta2 inhibits growth of uveal melanocytes at physiological concentrations. Exp Eye Res. 1998 Aug;67(2):143-50.

NY02:505769.1

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Attorney Docket No.
A35422 (073513.0102)

Application No.
10/670,971

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANTS**

Applicants
Hu et al.

Filing Date
September 24, 2003

Group Art Unit
1636

	13	Hu DN, McCormick SA, Orlow SJ, Rosemblat S, Lin AY. Regulation of melanogenesis by human uveal melanocytes in vitro. Exp Eye Res. 1997 Mar;64(3):397-404.
	14	Hu DN, McCormick SA, Orlow SJ, Rosemblat S, Lin AY, Wo K. Melanogenesis by human uveal melanocytes in vitro. Invest Ophthalmol Vis Sci. 1995 Apr;36(5):931-8.
	15	Hu DN, McCormick SA, Ritch R, Pelton-Henrion K. Studies of human uveal melanocytes in vitro: isolation, purification and cultivation of human uvea melanocytes. Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2210-9.
	16	Hu DN, McCormick SA, Ritch R. Studies of human uveal melanocytes in vitro: growth regulation of cultured human uveal melanocytes. Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2220-7.
	17	Loercher A.E, Harbour JW. Molecular genetics of uveal melanoma. Curr. Eye Res. 2003; 27, 69-74.
	18	Singh AD, Rennie IG, Seregard S, Giblin M, McKenzie J. Sunlight exposure and pathogenesis of uveal melanoma. Surv. Ophthalmol. 2004; 49, 419-28.
	19	ten Berge PJ, Danen EH, van Muijen GN, Jager MJ, Ruiter DJ. Integrin expressions in uveal melanoma differs from cutaneous melanoma. Invest Ophthalmol Vis Sci 1993; 34:3635-3640.

NY02:505769.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.